Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis

被引:48
|
作者
Kristen, Arnt V. [1 ]
Perz, Jolanta B. [2 ]
Schonland, Stefan O. [2 ]
Hansen, Alexander [1 ]
Hegenbart, Ute [2 ]
Sack, Falk-Udo [3 ]
Goldschmidt, Hartmut [2 ]
Katus, Hugo A. [1 ]
Dengler, Thomas J. [1 ]
机构
[1] Univ Heidelberg Hosp, Dept Cardiol, Dept Angiol & Resp Med, D-69120 Heidelberg, Germany
[2] Univ Heidelberg Hosp, Dept Haematol & Oncol, Heidelberg, Germany
[3] Univ Heidelberg Hosp, Dept Cardiac Surg, Heidelberg, Germany
来源
关键词
D O I
10.1016/j.healun.2007.09.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiac amyloidosis (CA) is the most problematic cause of heart failure because medical treatment strategies are not well tolerated. Due to its high mortality, identification of patients at high risk is crucial for treatment strategies such as heart transplantation prior to chemotherapy for amyloid disease. Methods: Left ventricular wall thickness (LVT) progression was retrospectively compared with electrocardiographic and echocardiographic parameters for risk prediction in 39 patients with histologically proven cardiac amyloidosis. Results: Seventeen deaths occurred, equivalent to 1- and 3-year survival rates of 62.1% and 55.0%, respectively. LVT progression in deceased patients was 2.02 +/- 0.85 mn/month compared with 0.19 +/- 0.03 mm/month in survivors (p < 0.001). Autologous stem-cell transplantation (n = 22, or 54%) reduced LVT progression as compared with not receiving stem cells (0.21 +/- 0.04 mm/month vs 1.45 +/- 0.57 mm/month, p < 0.005). LVT progression correlated with maximal LVT and absolute LVT increase. Progression of LVT was more rapid in patients with impaired LV ejection fraction (LVEF) than preserved LVEF (2.16 +/- 1.04 mm/month vs 0.30 +/- 0.13 mm/month, p < 0.001). LVT closely correlated with survival, whereas initial, maximum or absolute increase in LVT did not. Further predictors of survival were LVEF, autologous stem-cell transplantation and low voltage, but not diastolic dysfunction. Multivariate analysis identified LVT progression as the strongest independent parameter for survival. Conclusions: LVT progression is a powerful risk predictor in light-chain CA, superior to parameters such as LVEF, LVT or a low-voltage pattern. Improved survival by high-dose chemotherapy and stem-cell transplantation is paralleled by a reduction in LVT progression. Repetitive echocardiographic assessment appears indicated in CA patients to identify candidates for heart transplantation in amyloidosis. J Heart Lung Transplant 2007;26:1313-9. Copyright (c) 2007 by the International Society for Heart and Lung Transplantation.
引用
收藏
页码:1313 / 1319
页数:7
相关论文
共 50 条
  • [1] Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis
    Kristen, A. V.
    Perz, J. B.
    Schonland, S. O.
    Sack, F. U.
    Katus, H. A.
    Dengler, T. J.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (02): : S240 - S241
  • [2] Left atrial volume predicts mortality in light-chain amyloidosis
    Geenty, P.
    Sivapathan, S.
    Stefani, L. D.
    Zada, M.
    Taylor, M.
    Kwok, F.
    Thomas, L.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 113 - 114
  • [3] Left ventricular deformation in cardiac light-chain amyloidosis and hypereosinophilic syndrome
    Kormanyos Arpad
    Domsik Peter
    Kalapos Anita
    Marton Imelda
    Foldeak Dora
    Modok Szabolcs
    Gyenes Nandor
    Borbenyi Zita
    Nemes Attila
    [J]. ORVOSI HETILAP, 2020, 161 (05) : 169 - 176
  • [4] Predictors of progression of light-chain cardiac amyloidosis
    Rameeva, A. S.
    Vedanova, K. V.
    Rameev, V. V.
    Safarova, A. F.
    Bobkova, I. N.
    Kozlovskaya, L. V.
    Moiseev, S. V.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 1237 - 1237
  • [5] Global longitudinal left ventricular function predicts prognosis in systemic light-chain amyloidosis
    Buss, S. J.
    Mereles, D.
    Emami, M.
    Kristen, A.
    Schellberg, D.
    Galuschky, C.
    Hegenbart, U.
    Schoenland, S.
    Katus, H.
    Hardt, S.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 : 950 - 950
  • [6] Arrest of progression of cardiac amyloidosis after chemotherapy predicts favorable outcome in patients with light-chain amyloidosis
    Koyama, J.
    Minamisawa, M.
    Kuwahara, K.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 31 - 31
  • [7] Light-chain cardiac amyloidosis
    Mankad, Anit K.
    Sesay, Isata
    Shah, Keyur B.
    [J]. CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 144 - 156
  • [8] Assessment of Left Ventricular, Right Ventricular, and Left Atrial Strain in Light-Chain Amyloidosis
    Leedy, Douglas J.
    Vasbinder, Alexi
    Huang, Hans D.
    Fernandes, Robin
    Cowan, Andrew J.
    Gopal, Ajay K.
    Kirkpatrick, James N.
    Libby, Edward N.
    Cheng, Richard K.
    [J]. JACC: CARDIOONCOLOGY, 2020, 2 (04): : 647 - 649
  • [9] Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis
    Stamatelopoulos, Kimon
    Georgiopoulos, Georgios
    Athanasouli, Fani
    Nikolaou, Panagiota-Efstathia
    Lykka, Marita
    Roussou, Maria
    Gavriatopoulou, Maria
    Laina, Aggeliki
    Trakada, Georgia
    Charakida, Marietta
    Delialis, Dimitris
    Petropoulos, Ioannis
    Pamboukas, Constantinos
    Manios, Efstathios
    Karakitsou, Marina
    Papamichael, Christos
    Gatsiou, Aikaterini
    Lambrinoudaki, Irene
    Terpos, Evangelos
    Stellos, Konstantinos
    Andreadou, Ioanna
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    [J]. CIRCULATION RESEARCH, 2019, 125 (08) : 744 - 758
  • [10] Investigation of left ventricular function and biomarkers following treatment in patients with light-chain cardiac amyloidosis
    Wang, J.
    Yang, F.
    Zuo, L.
    Lei, C.
    Sheng, J.
    Sun, C.
    Liu, L.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 1237 - 1237